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TO THE EDITOR
Psoralen plus UVA (PUVA) lentigines
have been shown to develop in 40–50%
of patients after long-term PUVA treat-
ment (Rhodes et al., 1983; Abel et al.,
1985; Gupta et al., 1988). In addition to
individual susceptibility factors of race,
age, as well as tanning and burning
response to sunlight, PUVA lentigines
are related to the number of PUVA
treatments and total UVA dose and are
often found in patients who have
received an overdose, as indicated by
the development of sunburn-like photo-
toxic erythema (Ho¨nigsmann et al.,
1999). Clinically, PUVA lentigines pre-
sent as small brown unevenly pigmen-
ted lesions with irregular margins
occurring on PUVA-exposed body sites
(Basarab et al., 2000). Histologically,
they represent mainly a lentiginous
proliferation of functionally active mela-
nocytes, similar to solar lentigines. In
contrast to solar lentigines, melanocytes
in PUVA lentigines often display an
increased size of melanosomes, cluster-
ing and binucleation with nuclear
hyperchromatism, and cellular pleo-
morphism (Gupta et al., 1988). Abel
et al. (1985) found melanocytic atypia
consisting of large or angular hyper-
chromatic nuclei in 57% of PUVA
lentigines. Concern that PUVA lenti-
gines could be the precursors of mela-
nocyte dysplasia or malignancy has
been increased by the fact that PUVA
is known to be an effective proliferative
stimulus for melanocytes. For instance,
PUVA application enhances the incor-
poration of H3-thymidine in benign
melanocytic nevi (MN) and is asso-
ciated with intraepidermal dysplastic
melanocytic changes (Lagerholm and
Frithz, 1982). In vivo, PUVA stimulates
the growth of melanoma cells (Aubin
et al., 1991) and can induce melano-
cytic tumors in the mouse (Alcalay
et al., 1990). Indeed, several clinical
studies have suggested that chronic
PUVA exposure may lead to the forma-
tion of cutaneous malignant melanoma
(CMM) (Marx et al., 1983; Binet et al.,
1985; Gupta et al., 1988; Stern et al.,
1997; Wolf et al., 1998; Stern, 2001).
Most importantly, a recent follow-up of
the prospective US PUVA study showed
an increased incidence of CMM in
patients who had received more than
250 PUVA exposures (Stern et al.,
1997). PUVA may lead to CMM forma-
tion by its tumor initiating, promoting,
and/or immunosuppressive effects (Wolf
et al., 2004 and references cited therein),
possibly via PUVA lentigines as early
precursor lesions. However, a definite
pathogenic link between CMM and
PUVA lentigines has not been demon-
strated despite reports of PUVA lenti-
gines with more or less severe atypical
histologic features, persisting for years
after therapy has been discontinued
(Rhodes et al., 1983; Abel et al., 1985).
Thus, the long-term course of atypical
PUVA lentigines is still unknown as well
as the alterations on the molecular level
associated with these lesions.
B-type Raf (BRAF) mutations have
been detected in a high proportion of
CMM and MN (Brose et al., 2002;
Davies et al., 2002; Gorden et al.,
2003; Pollock et al., 2003; Uribe et al.,
2003; Lang and MacKie, 2005). The
serine/threonine protein kinase BRAF is
involved in the mitogen-activated pro-
tein kinase pathway that represents a
membrane-to-nucleus signaling cascade
regulating cell proliferation in response
to extracellular mitogenic signals. A
hotspot single mutation localized in
exon 15 (T1799A) at codon 600
(V600E) (former designation V599E
[T1796A]) of BRAF accounts for more
than 80% of mutations in melanoma
samples (Davies et al., 2002). As de-
monstrated by in vitro and in vivo
assays, abrogation of BRAFV600E leads
to growth arrest and apoptosis indicating
dependency of transformed phenotype
on this mutation in melanocytes (Hin-
gorani et al., 2003). In this study, we
analyzed PUVA lentigines, dysplastic
MN, and CMM from PUVA-treated
patients for BRAF mutations in exon 15
by an allele-specific (AS) PCR and direct
sequencing of PCR products in order to
gain insight into the molecular events of
PUVA-associated tumorigenesis.
Formalin-fixed and paraffin-
embedded material (surgical excisional
and/or punch biopsy specimens) of 33
PUVA-associated pigmented and/or
melanocytic lesions from 22 patients
was retrieved from the Division of
Dermatopathology, Department of
Dermatology, Medical University Graz.
Data concerning the PUVA treatment of
these patients were obtained from the
Research Unit for Photodermatology,
Department of Dermatology, Medical
University Graz. The lesions included
15 PUVA lentigines, 12 dysplastic MN,
and six CMM (two of them in situ). The
patient data and PUVA characteristics
are given in Table 1. All lentigines had
to be excised owing to clinical suspi-
cion of CMM (Figure 1a). CMM arose in
the PUVA-treated patients after a mean
time of 15 years (range 3–26 years)
following the first PUVA treatment, a
lag time consistent with a previous
report by Stern et al. (1997). All lesions
had undergone routine histology for
diagnosis, which was confirmed in a
re-evaluation by two experienced
dermatopathologists and coauthors (S.K.
and H.K.). Three of the lentigines from
the PUVA-treated patients showed parti-
cular severe melanocytic atypia, char-
acterized by a profound increase of
solitary, occasionally large, atypical mel-
anocytes at the dermo-epidermal junc-
tion and foci with solitary melanocytes in
higher levels of the epidermis (Figure 1b).
Mitotic figures were also noted in these
See related commentary on page 1693
Abbreviations: AS, allele-specific; CMM, cutaneous malignant melanoma; MN, melanocytic nevus;
PCR, polymerase chain reaction; PUVA, psoralen plus UVA
www.jidonline.org 1915
A Lassacher et al.
T1799A BRAF Mutation
PUVA lentigines. In one case, pagetoid
spread of solitary melanocytes was
accompanied by a pronounced epider-
mal hyperplasia. These lesions were
classified as PUVA lentigines with severe
atypia (Table 1). In addition, 15 ran-
domly selected melanomas and 14 MN
from non-PUVA-treated patients were
used as control samples for the possible
presence of the T1799A BRAF mutation.
All clinical and histological data were
collected after obtaining informed pa-
tient consent and the sampling was
carried out in accordance with the
Declaration of Helsinki Principles.
Sections (6 mm thick) of the paraffin-
embedded specimens were microdis-
sected to eliminate normal tissue and
Table 1. Clinical and histologic findings, PUVA characteristics, and BRAF mutation results in patients

























A F A1 60 Chest MN 8-MOP 247 1821 26 T1799A
B F B1 42 Thigh Lentigo 8-MOP 206 1021 8 T1799A1
B2 50 Shank Lentigo 8-MOP 844 4373 16 T1799A
B3 50 Leg Lentigo 8-MOP 844 4373 16
B4 53 Knee MN 8-MOP 996 5096 19 T1799A
C M C1 44 Back MN 8-MOP 31 152 1 T1799A
D M D1 55 Back MN 8-MOP 107 505 10
D2 55 Back CMM 8-MOP 107 505 10
E M E1 57 Shank Lentigo 8-MOP 30 46 9
F M F1 67 Back CMM (in situ) 8-MOP 1,430 8,580 20 T1799A
F2 67 Chest Lentigo 8-MOP 1,430 8,580 20
F3 67 Chest Lentigo with SA 8-MOP 1,430 8,580 20
F4 68 Shoulder Lentigo with SA 8-MOP 1,430 8,580 21
F5 66 Abdomen MN 8-MOP 1,430 8,580 19
F6 67 Abdomen Lentigo 8-MOP 1,430 8,580 20
G M G1 57 Upper arm CMM 8-MOP NA NA 21
H M H1 41 Shoulder MN 8-MOP 85 528 2 T1799A
I M I1 59 Thigh Lentigo 8-MOP NA NA 24 T1799A
J F J1 69 Thigh Lentigo 8-MOP 52 184 1 T1799A
K F K1 72 Upper arm Lentigo 8-MOP 511 3,156 17
L M L1 39 Abdomen Lentigo with SA 8/5-MOP 30 93 3
M M M1 62 Chest CMM 8-MOP NA NA 26 T1799A
N M N1 56 Buttocks MN 8-MOP 46 121 o1 T1799A
O F O1 26 Back MN 8-MOP 225 1,745 6 T1799A
P M P1 41 Abdomen CMM 5-MOP 67 352 3
Q M Q1 47 Buttocks MN 8-MOP 86 484 2 T1799A
M Q2 47 Back MN 8-MOP 86 484 2 T1799A
R M R1 73 Ear Lentigo 8/5-MOP 523 2,375 25
S F S1 68 Back Lentigo 8-MOP 19 42 6
T F T1 31 Back MN 8-MOP 75 113 4 T1799A1
T2 37 Chest MN 8-MOP 75 113 10 T1799A
U M U1 56 Chest Lentigo 8-MOP 418 1,847 18 T1799A
V F V1 46 Calf CMM (in situ) 8-MOP 31 56 11
CMM, cutaneous malignant melanoma (invasive, if not otherwise indicated); CN, congenital nevus; MN, melanocytic nevus; MOP, methoxypsoralen; SA,
severe atypia.
1Mutation was detected by direct sequencing and AS-PCR.
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obtain tissue with a content of more
than at least 30–50% melanocytes or
nevus cells. DNA extraction and direct
sequencing of BRAF exon 15 was
performed, as described previously
(Worda et al., 2005). AS-PCR for BRAF
T1799A was carried out with mutant-
specific primers and a pair of glycer-
aldehyde-3-phophate dehydrogenase
primers as internal control, as described
by Pollock et al. (2003) (primer se-
quences and PCR conditions available
from authors upon request). The AS-
PCR of DNA from melanocytic lesions
of PUVA-treated patients revealed that
T1799A BRAF mutation was present in
two of six (33%) CMM, 10 of 12 (83%)
MN, and five of 15 (33%) PUVA
lentigines (Table 1). AS-PCR of DNA
from melanocytic lesions of non-PUVA-
treated control patients disclosed
T1799A BRAF mutation in eight of 15
(53%) CMM and seven of 14 (50%)
MN. Direct sequencing of DNA from
all PUVA-associated melanocytic le-
sions showed T1799A BRAF mutated
in only two lesions (B1 and T1),
indicating that the AS-PCR is much
more sensitive than direct sequencing
for mutation detection (Miller et al.,
2004). Indeed, our own sensitivity
testing of the AS-PCR by diluting DNA
hetereozygous for the T1799A mutation
with wild-type DNA revealed that our
PCR setup was capable of detecting the
mutant allele when diluted to 0.4% of
the total DNA (data not shown).
To ensure reliability of the mutation
analysis, we always screened at least
one melanoma with a known T1799A
BRAF mutation obtained from a non-
PUVA-treated patient in conjunction
with the specimens of PUVA-treated
patients. The chance of false-negative
results in the group of PUVA-associated
lesions is not very high as the randomly
selected, simultaneously microdis-
sected and analyzed CMM from non-
PUVA-treated patients displayed a
mutation rate of 53% in CMM and
50% in MN, which is well in line with
published data showing a mutation rate
ranging from B20 to 90% in BRAF of
CMM and MN from the non-PUVA-
treated patient population (Brose et al.,
2002; Davies et al., 2002; Gorden
et al., 2003; Pollock et al., 2003; Uribe
et al., 2003; Lang and MacKie, 2005).
Taken together, this study demonstrates
that T1799A BRAF mutation is a com-
mon occurrence in PUVA lentigines
and perhaps in PUVA-associated CMM,
indicating that PUVA lentigines might
be precursors of CMM.
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Figure 1. PUVA lentigo with severe atypia (patient F, lesion F3). (a) Clinical features showing an
irregular, pigment lesion simulating CMM. (b) Histologic findings revealing hyperpigmentation of the
basal layer and an increase of relatively large, solitary melanocytes at the dermo-epidermal junction
as well as scattered melanocytes in higher layers of the epidermis.
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